Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Table 3

Incremental efficacy and cost-efficacy based on Physician’s Global Assessment clear or almost clear.

Biologics	Pooled incremental efficacy			6-month incremental cost-effectiveness ratio
	Base case	Best case	Worst case	Base case	Best case	Worst case
Etanercept	58%	71%	45%	$30,954	$25,287	$39,897
Adalimumab	56%	59%	52%	$23,980	$22,760	$25,824
Infliximab	69%	76%	63%	$28,587	$25,954	$31,310
Ustekinumab 45 mg	58%	64%	51%	$28,943	$26,229	$32,915
Ustekinumab 90 mg	62%	66%	58%	$54,151	$50,869	$57,886